Explore the clinical applications of weight management strategies to improve health and achieve sustainable results.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I present a comprehensive, first-person roadmap for understanding and treating obesity as a chronic, relapsing, and treatable disease. Drawing on modern, evidence-based research and clinical insights, I detail the neuroendocrine and metabolic mechanisms that drive weight regulation, examine the latest pharmacotherapies including GLP-1 and GIP/GLP-1 receptor agonists, and explain why integrative chiropractic care plays a vital role in restoring function and enabling sustained lifestyle change. I also highlight how weight bias undermines outcomes and share practical frameworks for compassionate care. Central to our approach at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, is our multidisciplinary model: I provide integrative chiropractic and functional medicine services in collaboration with our Medical Director, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), whose more than 40 years of internal medicine experience ensures rigorous medical oversight. Together, our team delivers tailored treatment—spanning medical management, rehabilitation, and functional health—that addresses the biomechanical, metabolic, and psychosocial dimensions of obesity.

Our Integrative Clinic Model: Chiropractic, Internal Medicine, and Functional Health

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, our care model reflects a simple truth: the human body is interconnected, and lasting health emerges when we address structure, metabolism, and behavior together. I serve patients as a chiropractor and advanced practice nurse with certifications in functional and integrative medicine. At the same time, our Medical Director, Dr. Maria Guadalupe Cardenas, MD, provides internal medicine oversight and prescriptive guidance. This multidisciplinary setup—common in integrative and injury care clinics—ensures that medical direction and chiropractic care work hand in hand.

• Medical Director and Collaborative Physician: Dr. Maria Guadalupe Cardenas, MD, Internal Medicine, NPI #1164426749, Texas License #J2933
• Chiropractic and Functional Medicine: Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST
• Location: Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), El Paso, Texas
• Clinical Services:

• • Medical oversight and diagnostics (internal medicine)
  • Integrative chiropractic care
  • Functional medicine and advanced laboratory analysis
  • Personal injury care and rehabilitation
  • Nutritional and lifestyle counseling
  • Coordinated care for complex chronic conditions, including obesity

This integrated framework allows us to align biomechanical restoration with metabolic optimization and behavioral support. In practical terms, it means we can reduce pain that blocks activity, prescribe evidence-based medications when indicated, and guide patients through nutrition, movement, and stress-modulation strategies that stick.

Redefining Obesity: A Chronic, Relapsing, Treatable Disease

Obesity is often miscast as a willpower failure. Modern research has established that obesity is a chronic, progressive, relapsing, and treatable disease—a finding recognized by leading medical organizations and codified in policy shifts that have reshaped clinical standards (American Medical Association, 2013).

Why does this redefinition matter? If a patient stops effective therapy for hypertension, blood pressure rises again; similarly, discontinuing effective anti-obesity treatments commonly leads to weight regain. This relapse is driven by a web of biological signals and environmental pressures, not moral shortcomings. The disease process centers on adipose tissue dysfunction—in which excess fat becomes an inflamed endocrine organ—disrupting hormonal signaling, insulin sensitivity, and systemic metabolic health, with downstream effects including osteoarthritis, metabolic syndrome, and psychosocial distress.

• Key disease mechanisms:

• Neurobehavioral drivers (conditioning, reward pathways)
• Neuroendocrine signals (satiety, hunger, stress hormones)
• Metabolic dysregulation (insulin signaling, lipid handling)
• Adipose tissue inflammation fueling further metabolic imbalance

When we treat obesity as a disease, we create space for science-guided solutions: differential diagnosis, pharmacotherapy targeting neural and hormonal pathways, structured lifestyle interventions, and the physical medicine supports that enable movement and resilience.

Citation: Recognition of obesity as a disease (American Medical Association, 2013).

The Social and Environmental Fabric of Obesity

Diagnosed at a BMI> 30, obesity affects 41.9% of Americans, with severe obesity (BMI ? 40) in 9.2%. These numbers are not uniform; they reflect social determinants of health that shape access, opportunity, and stress levels.

• Economic stability: Energy-dense, nutrient-poor foods are cheap and ubiquitous; fresh produce can be scarce in food deserts.
• Education and healthcare access: Limited resources reduce understanding and uptake of medical care.
• Neighborhood and built environment: Safety concerns and a lack of green spaces impede routine activities.
• Social context: Cultural norms around weight and food can hinder change or facilitate success.

Biology layers on top of environment. Ghrelin, GLP-1, and leptin orchestrate hunger and satiety, while the gut microbiome modulates energy extraction and inflammation. Our technology-enabled sedentary patterns amplify these signals, pushing energy balance toward storage.

The Hormonal Symphony: Appetite, Satiety, and Stress

The brain calibrates intake through continuous signaling from the gut, fat cells, and pancreas. I find that patients gain confidence when we demystify these systems—by understanding why “eat less, move more” often fails in the face of biology.

• Leptin: Secreted by adipocytes, leptin should signal “energy stores are adequate.” In obesity, leptin resistance blunts this message, maintaining hunger despite ample fat stores.
• Ghrelin: The “hunger hormone,” peaking pre-meal and dipping post-meal, encourages intake.
• GLP-1: Released after meals, GLP-1 slows gastric emptying, boosts insulin secretion, and amplifies satiety signals. It is the target of several breakthrough medications.
• Cortisol: Chronic stress elevates cortisol, biasing cravings toward sugar and fat and favoring visceral adiposity.

Pharmacotherapies that modulate satiety, slow gastric emptying, and recalibrate reward circuits can decisively tilt this hormonal symphony toward health. This is not about bypassing willpower—it’s about changing the informational landscape, so healthier choices feel attainable and satisfying.

References:

• Once-weekly semaglutide in adults with overweight or obesity (Wilding et al., 2021).
• GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists (Holst & Rosenkilde, 2020).
• Effects of once-daily liraglutide 3.0 mg on appetite and gastric emptying (Blundell et al., 2017).

Confronting Clinical Inertia and Weight Bias

A startling gap persists: fewer than 1% of Americans with obesity receive anti-obesity prescriptions. Clinical inertia and weight bias are chief culprits. Weight bias remains widespread—and has increased—even as other social biases decline (Puhl & Heuer, 2010). This bias dampens care-seeking, erodes trust, and worsens outcomes independent of BMI.

• Common manifestations of bias:

• • Attributing obesity to character flaws or laziness
  • Avoiding clinical conversations about weight
  • Underutilizing effective therapies due to stigma or misinformation

I use the 5 A’s to anchor compassionate, productive care:

• Ask: “Would it be okay if we discussed your weight and its impact on health?”
• Assess: History, family factors, past attempts, lifestyle habits, comorbidities, medications.
• Advise: Explain the benefits of even 3–5% weight loss for metabolic health.
• Agree: Collaborate on realistic, patient-defined goals.
• Arrange/Assist: Build supports—dietitian, behavioral therapy, exercise physiology—and schedule follow-ups.

References:

• Obesity stigma: Important considerations for public health (Puhl & Heuer, 2010).
• Pharmacological management of obesity: Endocrine Society guideline (Apovian et al., 2015).

A Tiered, Evidence-Based Strategy for Obesity Management

I structure care based on BMI and comorbidity burden, then personalize within that framework:

• BMI> 25 with comorbidities: Intensive lifestyle interventions—nutritional counseling, physical activity, behavioral therapy.
• BMI> 27 with comorbidities or BMI? 30: Add pharmacotherapy to lifestyle measures.
• BMI> 35 with comorbidities or BMI?40: Discuss bariatric surgery, which can be life-saving for many.

A practical milestone is a 5–10% weight loss within six months; this level of change can meaningfully affect blood pressure, A1C, lipids, and inflammatory markers.

Integrative Chiropractic Care: Reducing Pain, Restoring Function, Enabling Activity

From my chiropractic and functional perspective, excess weight imposes substantial biomechanical strain. Pain is a profound barrier to movement—and without movement, metabolic health falters. My role is to help patients reclaim pain-free motion.

• Common pain syndromes in obesity:

• • Low back pain and sciatica
  • Osteoarthritis of knees/hips
  • Plantar fasciitis
  • Degenerative disc disease

How chiropractic care fits:

• Spinal and joint adjustments: Restore joint mechanics, reduce nociceptive signaling, and improve mobility.
• Neuromuscular re-education: Optimize movement patterns and reduce compensatory overload on joints.
• Soft-tissue therapies: Reduce myofascial restriction and improve circulation.
• Posture optimization: Counter increased lumbar lordosis and altered center of gravity.

Why it works: When pain decreases, patients can adhere to exercise prescriptions—strengthening musculature, improving insulin sensitivity, and amplifying caloric flux. Chiropractic care thus becomes a catalyst for metabolic interventions, not a parallel track.

Clinical observations and insights:

• My clinical notes and case reflections, including those shared at com and on my professional profile on LinkedIn (Dr. Alex Jimenez), consistently highlight that addressing spinal mechanics and regional joint dysfunction early in the weight-loss journey increases adherence to activity plans and improves long-term outcomes. Patients who regain comfortable gait and lumbar stability are more likely to sustain the movement patterns that keep weight off.

First, Do No Harm: Identifying and Replacing Obesogenic Medications

Before initiating any anti-obesity therapy, we audit existing medications for obesogenic effects. Many patients unknowingly take drugs that promote weight gain; de-prescribing or substituting can produce immediate benefits.

• Drugs to watch:

• • Some antidepressants (selected SSRIs, tricyclics)
  • Antipsychotics and mood stabilizers (e.g., olanzapine, valproate)
  • Antidiabetic agents (e.g., sulfonylureas, insulin)
  • Corticosteroids (e.g., prednisone)

Example: In a patient with type 2 diabetes on a sulfonylurea, reevaluating therapy and introducing a GLP-1 receptor agonist or SGLT2 inhibitor can both improve glycemic control and facilitate weight reduction.

Reference: Pharmacological management of obesity: Endocrine Society guideline (Apovian et al., 2015).

The Pharmacological Toolkit: Modern Anti-Obesity Therapies

Medications are not magic bullets; they are targeted instruments that alter biological signaling. When combined with lifestyle and functional care, they can produce durable, health-protective weight loss.

Short-term therapy:

• Phentermine: A sympathomimetic appetite suppressant approved for up to 12 weeks. Off-label longer use exists among specialists with careful monitoring. We watch for tachyphylaxis and monitor blood pressure/heart rate.

Long-term therapies:

• Orlistat (Xenical, Alli): Lipase inhibitor reducing fat absorption by about 30%. Behavioral reinforcement occurs because high-fat intake triggers GI side effects—discouraging fat-rich meals.
• Phentermine/Topiramate ER (Qsymia): Potent combination—appetite suppression plus increased satiety and possible leptin modulation. Requires titration and teratogenicity counseling.
• Naltrexone/Bupropion ER (Contrave): Targets POMC neurons and reward pathways—reducing cravings and increasing energy expenditure. Useful when depression coexists with weight challenges.
• Liraglutide (Saxenda): Daily GLP-1 receptor agonist; mimics endogenous GLP-1 to slow gastric emptying and amplify satiety.
• Semaglutide (Wegovy): Weekly GLP-1 receptor agonist with robust efficacy for weight reduction (Wilding et al., 2021).
• Tirzepatide (Zepbound): Weekly dual GIP/GLP-1 receptor agonist—currently the most powerful agent in class, with superior average weight loss outcomes (Jastreboff et al., 2022).

Safety considerations: GLP-1 and GIP/GLP-1 therapies carry warnings for pancreatitis and are contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2. We screen meticulously and provide clear safety education before initiation.

References:

• Once-weekly semaglutide in adults with overweight or obesity (Wilding et al., 2021).
• Tirzepatide once weekly for the treatment of obesity (Jastreboff et al., 2022).
• GIP as a therapeutic target in diabetes and obesity (Holst & Rosenkilde, 2020).
• Effects of once-daily liraglutide 3.0 mg (Blundell et al., 2017).

Clinical Case Thinking: Individualizing Treatment

Case 1: Type 2 Diabetes, Hypertension, Hyperlipidemia

A 45-year-old on glyburide struggles with weight. My first move is to de-prescribe obesogenic drugs—consider discontinuing the sulfonylurea—then optimize metformin (often to 1,000 mg twice daily absent GI limitations). With a diabetes diagnosis, semaglutide (Ozempic) becomes accessible via insurance, addressing glycemia, satiety, and cardiovascular risk simultaneously.

Case 2: BMI 34, Prediabetes, Depression

For a 38-year-old male with hypertension and mood symptoms, I confirm diabetes status via A1C and fasting glucose to expand coverage options. Naltrexone-bupropion (Contrave) is compelling: bupropion addresses depression and appetite; naltrexone dampens reward-driven cravings. We titrate slowly and pair with chiropractic care to enable comfortable exercise.

Case 3: BMI 31, Binge Eating Disorder, Anxiety

A 32-year-old female with BED benefits from lisdexamfetamine (Vyvanse)—FDA-approved for moderate-to-severe BED—which reduces binge frequency by improving impulse control. We start low (e.g., 30 mg daily), monitor blood pressure/heart rate, and carefully assess anxiety responses, as stimulants can either exacerbate or alleviate anxiety depending on neurochemical context. Chiropractic support helps reduce somatic tension and improve sleep and movement quality.

Guiding Principles for Medication Use

• First, do no harm: Replace obesogenic medications when feasible.
• Screen contraindications: Avoid phentermine in uncontrolled hypertension or coronary disease; avoid GLP-1 agents in MEN 2 or a history of medullary thyroid carcinoma.
• Individualize therapy: Align potency with goals and comorbidities—e.g., consider tirzepatide for greater total weight loss needs.
• Monitor outcomes and set realistic goals: Expect at least 5% weight loss by 3 months at therapeutic dose; discontinue agents that do not meet benchmarks.
• Shared decision-making: Discuss side effects, costs, and delivery preferences (weekly injections vs. oral agents); adherence grows when patients co-author their plan.

References:

• Pharmacological management of obesity: Endocrine Society guideline (Apovian et al., 2015).
• Obesity Playbook (The Endocrine Society, n.d.).

---

Discovering the Benefits of Chiropractic Care- Video

---

Rehabilitation and Personal Injury Care: Building Capacity for Movement

Weight commonly complicates injury recovery by increasing joint loads and prolonging tissue stress. Our rehabilitation team delivers graded exercise prescriptions to build lean mass, improve balance, and restore gait mechanics. Chiropractic adjustments accelerate this process by normalizing joint play and reducing pain, while functional medicine protocols support tissue healing and inflammation control.

• Rehabilitation focus areas:

• • Core stabilization to support lumbar spine
  • Hip-knee-ankle kinetic chain alignment
  • Progressive resistance training for muscle preservation
  • Low-impact aerobic conditioning to enhance mitochondrial efficiency

Why this matters: Preserving and expanding lean muscle mass improves basal metabolic rate, glucose disposal, and metabolic resilience. Patients who move better and hurt less sustain activity—and sustained activity underpins durable weight management.

What’s Next: The Future of Obesity Treatment

The pipeline for obesity therapies is rich and promising:

• Retatrutide (“Triple G” ): A GIP/GLP-1/glucagon co-agonist with up to 24% total body weight loss over 48 weeks and signals of lean mass preservation—a vital metric for long-term metabolic health (Suran, 2024).
• Oral GLP-1s: Agents like Rybelsus (oral semaglutide) and investigational molecules (e.g., orforglipron) expand options for needle-averse patients.
• Novel mechanisms: Bimagrumab, a monthly infusion targeting activin receptors, has shown reductions in fat mass and increases in lean mass—heralding a paradigm in which weight interventions sculpt body composition strategically.

Reference: The future of obesity treatment (Suran, 2024).

Why Integrative Care Works: The Mission Plaza Model

Our model brings together the structural and metabolic pillars of health:

• Chiropractic care (Dr. Jimenez): Relieves pain, restores alignment, enables exercise adherence.
• Internal medicine oversight (Dr. Cardenas): Diagnoses comorbidities, prescribes and manages advanced pharmacotherapies, ensures safety.
• Functional medicine (Dr. Jimenez): Investigates root causes—hormonal imbalances, gut dysbiosis, nutrient deficiencies—and corrects them.
• Rehabilitation and personal injury care: Rebuilds movement confidence and muscular capacity.
• Lifestyle and behavioral coaching: Anchors habits that sustain results.

This comprehensive approach addresses how patients feel, how they move, and how their metabolism operates—creating synergies that single-modality care cannot match. Across my clinical practice and shared observations on ChiropracticScientist.com and LinkedIn, the lesson is clear: when we treat pain, biology, and behavior together, patients achieve more—and they keep it.

References

• Recognition of obesity as a disease. American Medical Association. (2013). Resolution 420: Recognition of obesity as a disease.

• Pharmacological management of obesity: An Endocrine Society clinical practice guideline. Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., & Still, C. D. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362.

• Obesity stigma: Important considerations for public health. Puhl, R. M., & Heuer, C. A. (2010). Obesity stigma: Important considerations for public health. American Journal of Public Health, 100(6), 1019–1028.

• Once-weekly semaglutide in adults with overweight or obesity. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., & Wadden, T. A. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.

• Tirzepatide once-weekly for the treatment of obesity. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., & The SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.

• GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists.Holst, S., & Rosenkilde, M. J. (2020). GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists. Journal of Medicinal Chemistry, 63(13), 6615–6626.

• Effects of once-daily liraglutide 3.0 mg on appetite, energy intake, and gastric emptying in obese adults. Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-daily liraglutide 3.0 mg on appetite, energy intake, and gastric emptying in obese adults. Diabetes, Obesity and Metabolism, 19(9), 1242–1251.

• Obesity Playbook. The Endocrine Society. (n.d.). Obesity Playbook.

• The future of obesity treatment Suran, M. (2024). The future of obesity treatment. JAMA, 331(12), 988–990.

SEO Tags: obesity treatment, integrative chiropractic care, functional medicine, GLP-1 agonists, tirzepatide, semaglutide, phentermine, Contrave, lisdexamfetamine, binge eating disorder, weight bias, clinical inertia, Injury Medical Clinic, Mission Plaza Injury Medical Clinic, El Paso Texas, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, internal medicine oversight, metabolic health, rehabilitation, personal injury care, leptin resistance, ghrelin, GLP-1, GIP, retatrutide, bimagrumab